Gaspar M, Bovaira M, Carrera-Hueso F J, Querol M, Jiménez A, Moreno L
Servicio de Farmacia, Centro de Recuperación y Rehabilitación de Levante, Valencia, España.
Farm Hosp. 2012 Sep-Oct;36(5):385-91. doi: 10.1016/j.farma.2011.10.009. Epub 2012 Jan 21.
Evaluate the efficacy of a topical treatment protocol with DMSO 50% to alleviate inflammatory processes in type 1 complex regional pain syndrome (CRPS) with a course of less than 1 year.
Retrospective study performed in a traumatology hospital on patients with type 1 CRPS for whom a standard treatment algorithm was prescribed with stepwise administration of oral drugs and interventional techniques. Patients also received topical DMSO 50% cream as a magistral formula. The follow-up period, lasting until patient discharge, or during 1 year for persistent cases, included 6 visits: baseline, 15 days, 1 month, 3 months, 6 months, and 1 year. The evaluation was performed using a visual analogue scale (VAS) as the main efficacy variable. Secondary variables were the Likert scale for quality of life and the limb capacity variable (range of motion, strength, overall limb function). A questionnaire designed for the study was also given.
Overall decrease in VAS score in the 29 patients was 3.09 points. The Likert scale score increased by 1.36 points. The scores measuring limb capacity increased to 12.03 for range of motion and to 3 in strength with overall function rated «moderate».
Topical application of DMSO 50% associated with a treatment algorithm decreased pain intensity according to the VAS score with results approaching absence of pain, and led to higher scores on the quality of life questionnaire. Topical DMSO 50% is an additional tool for use in treating CRPS I. Its side effects are scarce and it provides an overall sense of relief and lessens rigidity.
评估使用50%二甲基亚砜(DMSO)的局部治疗方案对病程不足1年的1型复杂性区域疼痛综合征(CRPS)炎症过程的缓解效果。
在一家创伤医院对1型CRPS患者进行回顾性研究,为这些患者制定了标准治疗方案,逐步给予口服药物和介入技术治疗。患者还接受了作为经验配方的50% DMSO局部乳膏治疗。随访期持续至患者出院,对于持续性病例则为1年,包括6次就诊:基线、15天、1个月、3个月、6个月和1年。使用视觉模拟量表(VAS)作为主要疗效变量进行评估。次要变量为生活质量的李克特量表和肢体能力变量(活动范围、力量、肢体整体功能)。还发放了专门为该研究设计的问卷。
29例患者的VAS评分总体下降了3.09分。李克特量表评分提高了1.36分。肢体能力测量得分中,活动范围提高到12.03,力量提高到3,整体功能评定为“中等”。
与治疗方案联合使用的50% DMSO局部应用根据VAS评分降低了疼痛强度,结果接近无痛,并使生活质量问卷得分更高。50% DMSO局部应用是治疗I型CRPS的一种额外工具。其副作用较少,能带来整体的缓解感并减轻僵硬程度。